Commonwealth Numbered Regulations

[Index] [Table] [Search] [Search this Regulation] [Notes] [Noteup] [Previous] [Download] [Help]

NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS AMENDMENT 1979 NO. 250 - SCHEDULE 4

Regulation 9

AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit the heading to the Schedule, substitute the following heading:

"PRESCRIBING OF PHARMACEUTICAL BENEFITS SUBJECT TO CONDITIONS AND RESTRICTIONS".

2. Omit the heading to column 3, substitute the following heading:

"Column 3
Persons for whose treatment,
diseases or conditions for the
treatment of which, purposes
for which, and conditions
subject to which, the
pharmaceutical benefit may be
prescribed for supply under
Part VII of the Act".

3. Omit item 3.
4. Omit item 4.
5. Omit item 5.
6. Omit item 8.
7. Omit item 11, substitute the following item:

"11


Azathioprine Tablets, B.P


Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Permanent Head-
Anaemia, autoimmune haemolytic
Arthritis, rheumatoid with vasculitis or visceral complications
Continuing azathioprine therapy after discharge from a hospital
Crohn's disease
Dermatomyositis
Granulomatosis, Wegener's
Hepatitis, active, chronic
Lupus erythematosus, systemic
Nephritis
Nephrotic syndrome
Organ transplant
Pemphigus
Polyarteritis nodosa
Pyoderma gangrenosum
Scleroderma
Thrombocytopenic purpura
Ulcerative colitis".


8. Omit item 24, substitute the following item:

"24


Carbenicillin Sodium


Any disease or condition in a patient receiving treatment in or at an approved hospital
Infections where positive bacteriological evidence confirms that carbenicillin is the most appropriate therapeutic agent
Septicaemia, suspected or proven".


9. Omit item 33, substitute the following item:

"33


Chlorambucil Tablets, B.P


Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Permanent Head-
Anaemia, autoimmune, haemolytic
Arthritis, rheumatoid with vasculitis or visceral complications
Continuing chlorambucil therapy after discharge from a hospital
Crohn's disease
Dermatomyositis
Granulomatosis, Wegener's
Hepatitis, active chronic
Lupus erythematosus, systemic
Malignant disease including leukaemia
Nephritis
Nephrotic syndrome
Polyarteritis nodosa
Scleroderma
Thrombocytopenic purpura
Ulcerative colitis".


10. Omit item 44.
11. Omit item 51, substitute the following item:

"51


(1) Cyclophosphamide, B.P.
(2) Cyclophosphamide Tablets, B.P.


Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Permanent Head-
Anaemia, autoimmune, haemolytic
Arthritis, rheumatoid with vasculitis or visceral complications
Continuing cyclophosphamide therapy after discharge from a hospital
Crohn's disease
Dermatomyositis
Granulomatosis, Wegener's
Hepatitis, active, chronic
Lupus erythematosus, systemic
Malignant disease, including leukaemia
Nephritis
Nephrotic syndrome
Pemphigus
Polyarteritis nodosa
Scleroderma
Thrombocytopenic purpura
Ulcerative colitis".


12. Omit item 66, substitute the following item:

"66


(1) Disopyramide
(2) Disopyramide Phosphate


Cardiac arrhythmias, when other anti-arrhythmic drug therapy is unsatisfactory".


13. Omit item 67.
14. Omit item 73.
15. Omit item 89.
16. Omit item 90, substitute the following item:

"90


(1) Idoxuridine Eye Drops
(2) Idoxuridine Eye Ointment


Eye infections caused by Herpes Simplex Virus or by Vaccinia Virus".


17. After item 93 insert the following item:

"93A


Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.


Ileostomy or colostomy conditions".


18. Omit item 97.
19. Omit item 99.
20. Omit item 101.
21. Omit item 111, substitute the following item:

"111


(1) Methotrexate Injection
(2) Methotrexate Tablets


Any disease or condition in a patient receiving treatment in or at an approved hospital
With the written authority of the Permanent Head-
Continuing methotrexate therapy after discharge from a hospital
Malignant neoplasia
Pemphigus
Severe intractable or extensive psoriasis ".


22. Omit item 117, substitute the following item:

"117


Metoclopramide Hydrochloride 10 mg Tablets


With the written authority of the Permanent Head-
Gastric retention after gastric surgery".


23. Omit item 119.
24. Omit item 121, substitute the following item:

"121


Morphine Sulphate, B.P. with Tacrine Hydrochloride Tablets


Severe intractable pain".


25. Omit item 132.
26. Omit item 133.
27. Omit item 144.
28. Omit item 145.
29. Omit item 147.
30. Omit item 151, substitute the following item:

"151


Potassium Bicarbonate Effervescent Tablets


With the written authority of the Permanent Head-
Hyperchloraemic hypokalaemic acidosis".


31. Omit item 152.
32. Omit item 158.
33. Omit item 159, substitute the following item:

"159


Propranolol Tablets, B.P. 160 mg


With the written authority of the Permanent Head-
Hypertension where there is an inadequate response to a daily dose of at least 160 mg of propranolol
Frequent disabling agina without evidence of cardiac failure where there is an inadequate response to a daily dose of at least 160 mg of propranolol".


34. Omit item 167.
35. Omit item 170, substitute the following item:

"170


Spironolactone Tablets, B.P.


With the written authority of the Permanent Head-
Primary hyperaldosteronism
Secondary hyperaldosteronism".


36. Omit item 173.
37. Omit item 181, substitute the following item:

"181


Timolol Maleate Eye Drops


With the written authority of the Permanent Head-
Open-angle glaucoma".


1. Notified in the Commonwealth of Australia Gazette on 30 November 1979.

2. Statutory Rules 1960 No. 17 as amended to date. For previous amendments see Note 2 to Statutory Rules 1979 No. 51 and see also Statutory Rules 1979 Nos. 51, 55 and 144.


AustLII: Copyright Policy | Disclaimers | Privacy Policy | Feedback